HOUT-26. SURVIVAL OUTCOMES IN GLIOBLASTOMA PATIENTS USING TTFIELDS: THE BAYLOR SCOTT & WHITE MEDICAL CENTER IN CENTRAL TEXAS EXPERIENCE

Abstract BACKGROUND Glioblastoma is a CNS cancer with extremely poor survival rates despite advances in chemoradiation therapy. TTFields (Optune) are an FDA approved option for treatment of glioblastoma. PURPOSE: This article aims to determine whether Optune compliance rates in patients with both newly diagnosed and recurrent glioblastoma affects survival. METHODS/ANALYSIS: A comprehensive list of glioblastoma patients was extracted from the Baylor Scott & White tumor registry from 2012–2018. Data on compliance, demographics, IDH/MGMT status and survival was compiled on Optune users. These variables were analyzed using the Welch T-test to ascertain their impact on compliance and survival. A Pearson correlation coefficient was calculated to determine the relationship between compliance and survival post-Optune. RESULTS 37 patients were identified (median age: 60, range: 21–86). Males were more affected (60.0%), the frontal lobe was the most common site (35.1%), and the median survival was 17 months. There was no statistical difference in survival length (months) based on gender (males = 21.5, females = 18.9, p = 0.52), MGMT status (methylated = 21.8, unmethylated = 17.8, p = 0.40), and IDH status (wild = 19.1, mutated = 30.2, p = 0.41). The average Optune compliance was 66.2%, with no statistical difference based on age (age 50 = 71.1%, p = 0.06) and gender (male = 66.6%, female = 65.6%, p = 0.89). The correlation coefficient comparing compliance and survival post-Optune was R = -0.247 (p = 0.141). CONCLUSION Studies have shown that Optune compliance of 75% or greater can improve outcomes. In our own limited study, the average compliance was markedly below at 66.2%, with no impact on the median 17-month survival. Age and gender did not play a role in compliance rates. This illustrates that further education is required in central Texas to improve compliance and patient outcomes.